SEARCH

SEARCH BY CITATION

References

  • Andreopoulou E., Chen T., Liebes L., Curtin J., Blank S., Wallach R., Hochster H. and Muggia F. (2011) Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemother. Pharmacol. 68, 457463.
  • Barrera N. P., Herbert P., Henderson R. M., Martin I. L. and Edwardson J. M. (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc. Natl Acad. Sci. USA 102, 1259512600.
  • Billio A., Morello E. and Clarke M. J. (2010) Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst. Rev. Issue 1, CD006272.
  • Brady C. A., Stanford I. M., Ali I., Lin L., Williams J. M., Dubin A. E., Hope A. G. and Barnes N. M. (2001) Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology 41, 282284.
  • Champaneria S., Costall B., Naylor R. J. and Robertson D. W. (1992) Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract. Br. J. Pharmacol. 106, 693696.
  • Das P. and Dillon G. H. (2003) The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res. Mol. Brain Res. 119, 207212.
  • Davies P. A. (2011) Allosteric modulation of the 5-HT(3) receptor. Curr. Opin. Pharmacol. 11, 7580.
  • Davies P. A., Pistis M., Hanna M. C., Peters J. A., Lambert J. J., Hales T. G. and Kirkness E. F. (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397, 359363.
  • Forbes C., Shirran L., Bagnall A. M., Duffy S. and ter Riet G. (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol. Assess. 5, 1110.
  • Green T., Stauffer K. A. and Lummis S. C. (1995) Expression of recombinant homo-oligomeric 5-hydroxytryptamine3 receptors provides new insights into their maturation and structure. J. Biol. Chem. 270, 60566061.
  • Hapfelmeier G., Tredt C., Haseneder R., Zieglgansberger W., Eisensamer B., Rupprecht R. and Rammes G. (2003) Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys. J. 84, 17201733.
  • Herrstedt J. and Dombernowsky P. (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin. Pharmacol. Toxicol. 101, 143150.
  • Hussy N., Lukas W. and Jones K. A. (1994) Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: comparison with native mouse receptors. J. Physiol. 481(Pt 2), 311323.
  • Kilpatrick G. J., Jones B. J. and Tyers M. B. (1989) Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur. J. Pharmacol. 159, 157164.
  • Kobayashi K., Hino M., Fukuoka M. et al. (2002) Phase I studies of nogitecan hydrochloride for Japanese. Int. J. Clin. Oncol. 7, 177186.
  • Krieg P. A. and Melton D. A. (1984) Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 12, 70577070.
  • Krzywkowski K., Davies P. A., Feinberg-Zadek P. L., Brauner-Osborne H. and Jensen A. A. (2008) High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc. Natl Acad. Sci. USA 105, 722727.
  • Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T. and Mutai M. (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47, 59445947.
  • Lester H. A., Dibas M. I., Dahan D. S., Leite J. F. and Dougherty D. A. (2004) Cys-loop receptors: new twists and turns. Trends Neurosci. 27, 329336.
  • Lochner M. and Lummis S. C. (2010) Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor. Biophys. J. 98, 14941502.
  • Lovinger D. M. and White G. (1991) Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol. Pharmacol. 40, 263270.
  • Lummis S. C., Beene D. L., Lee L. W., Lester H. A., Broadhurst R. W. and Dougherty D. A. (2005) Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438, 248252.
  • Maksay G., Thompson S. A. and Wafford K. A. (2000) Allosteric modulators affect the efficacy of partial agonists for recombinant GABA(A) receptors. Br. J. Pharmacol. 129, 17941800.
  • Nakamura Y., Ishida Y., Yamada T. and Shimada S. (2011) Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses. Biochem. Biophys. Res. Commun. 415, 416420.
  • Niesler B., Frank B., Kapeller J. and Rappold G. A. (2003) Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310, 101111.
  • Niesler B., Walstab J., Combrink S., Moller D., Kapeller J., Rietdorf J., Bonisch H., Gothert M., Rappold G. and Bruss M. (2007) Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol. Pharmacol. 72, 817.
  • O'Brien M., Eckardt J. and Ramlau R. (2007) Recent advances with topotecan in the treatment of lung cancer. Oncologist 12, 11941204.
  • Peng L. H., Chen X. Y. and Wu T. X. (2008) Topotecan for ovarian cancer. Cochrane Database Syst. Rev. Issue 2, CD005589.
  • Pratt G. D. and Bowery N. G. (1989) The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat. Neuropharmacology 28, 13671376.
  • Shah D. K. and Balthasar J. P. (2011) Physiologically based pharmacokinetic model for topotecan in mice. J. Pharmacokinet Pharmacodyn. 38, 121142.
  • Solt K., Stevens R. J., Davies P. A. and Raines D. E. (2005) General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J. Pharmacol. Exp. Ther. 315, 771776.
  • Stevens R., Rusch D., Solt K., Raines D. E. and Davies P. A. (2005) Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J. Pharmacol. Exp. Ther. 314, 338345.
  • Sugai T., Suzuki Y., Sawamura K., Fukui N., Inoue Y. and Someya T. (2006) The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 6, 351356.
  • Thompson S. A., Wingrove P. B., Connelly L., Whiting P. J. and Wafford K. A. (2002) Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors. Mol. Pharmacol. 61, 861869.
  • Thompson A. J., Duke R. K. and Lummis S. C. (2011) Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol. Pharmacol. 80, 183190.
  • Tischbirek C. H., Wenzel E. M., Zheng F. et al. (2012) Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron 74, 830844.
  • Trattnig S. M., Harpsoe K., Thygesen S. B., Rahr L. M., Ahring P. K., Balle T. and Jensen A. A. (2012) Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of cys-loop receptor signaling through a conserved transmembrane intersubunit site. J. Biol. Chem. 287, 2524125254.
  • Tyers M. B. and Freeman A. J. (1992) Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 49, 263268.
  • Walstab J., Hammer C., Bonisch H., Rappold G. and Niesler B. (2008) Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors. Pharmacogenet. Genomics 18, 793802.
  • Yang J., Mathie A. and Hille B. (1992) 5-HT3 receptor channels in dissociated rat superior cervical ganglion neurons. J. Physiol. 448, 237256.